Yael Weiss Is currently CEO of Mahzi Therapeutics, a company focused on the development of therapies for ultra-rare genetic neurodevelopmental disorders. Mahzi works closely with patient foundations to support their journey towards drug development and bring programs into Mahzi once pre-clinical proof of concept is established.

Yael completed her MD at Hadassah Medical School at the Hebrew University in Jerusalem and her PhD  at the Weizmann Institute of Science in Rehovot, Israel. She has over 20 years of industry experience in medical/clinical and business development roles at Genzyme, Merck and Ultragenyx.

Yael is a member of ASGCT and AES translational committee, N=1 collaborative and is a 2022 Termeer Fellow. Board member/advisor to Everlum and ADNP,  FOXG1 KCNT1 and Team Telomere foundations.